Literature DB >> 23496086

Hospital admission due to infections in multiple sclerosis patients.

S Montgomery1, J Hillert, S Bahmanyar.   

Abstract

BACKGROUND AND
PURPOSE: Multiple sclerosis (MS) patients are at increased infection risk. Here the influences of susceptibility, severity and surveillance bias on infection-related hospital admission are assessed.
METHODS: Swedish registers identified 20,276 patients with MS, matched with 203,951 people from the general population without MS. Risk of first hospital admission for infection and mortality over 36 years was estimated by Poisson regression.
RESULTS: Multiple sclerosis was associated with an increased hospital admission risk for all infections, with an adjusted relative risk (and 95% confidence interval) of 4.26 (4.13-4.40). A proportion of this raised risk was probably due to surveillance and referral bias, although a raised risk remained when MS was compared with other immune-mediated diseases. The 1-month mortality rate following hospital admission for infection was higher in MS patients than in the comparison cohort, with a relative risk of 4.69 (4.21-5.22). There was no clear temporal trend in the results, and risks were higher in males and varied by MS phenotype.
CONCLUSIONS: Higher hospital admission rates among MS patients for infection are likely to be due to a combination of surveillance bias, cautious medical management and greater susceptibility to severe infections. MS-related functional limitations may increase infection risk and this should be considered in MS management.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  hospital admission; infection; mortality; multiple sclerosis

Mesh:

Year:  2013        PMID: 23496086     DOI: 10.1111/ene.12130

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  32 in total

1.  Measurement of mucociliary clearance in the patients with multiple sclerosis.

Authors:  Ender Sahin; Mehmet Hamamcı; Yunus Kantekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-11-09       Impact factor: 2.503

2.  Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans.

Authors:  Richard E Nelson; Yan Xie; Scott L DuVall; Jorie Butler; Aaron W C Kamauu; Kristin Knippenberg; Markus Schuerch; Nadia Foskett; Joanne LaFleur
Journal:  Int J MS Care       Date:  2015 Sep-Oct

3.  Burn injury and multiple sclerosis: A retrospective case-control study.

Authors:  Matthew R McCann; William F Hill; Jinhui Yan; Sarah Rehou; Marc G Jeschke
Journal:  Burns       Date:  2018-11-23       Impact factor: 2.744

4.  Uptake and Attitudes About Immunizations in People With Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2021-08

5.  COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy.

Authors:  Andrew Wolf; Enrique Alvarez
Journal:  Neurol Clin Pract       Date:  2021-08

6.  Readmission Rates in Patients With Multiple Sclerosis: A Nationwide Cohort Study.

Authors:  Akhil Padarti; Amod Amritphale; William Kilgo
Journal:  Int J MS Care       Date:  2022-05-03

7.  Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-22

8.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

9.  Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Authors:  Gustavo Luna; Peter Alping; Joachim Burman; Katharina Fink; Anna Fogdell-Hahn; Martin Gunnarsson; Jan Hillert; Annette Langer-Gould; Jan Lycke; Petra Nilsson; Jonatan Salzer; Anders Svenningsson; Magnus Vrethem; Tomas Olsson; Fredrik Piehl; Thomas Frisell
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

10.  Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Authors:  Christoph Metze; Alexander Winkelmann; Micha Loebermann; Michael Hecker; Brunhilde Schweiger; Emil Christian Reisinger; Uwe Klaus Zettl
Journal:  CNS Neurosci Ther       Date:  2018-07-25       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.